<DOC>
	<DOCNO>NCT01743560</DOCNO>
	<brief_summary>Determine overall response rate ( ORR ) 48 week everolimus ( RAD001 , 10mg daily p.o . ) exemestane ( 25mg daily p.o . ) treatment postmenopausal woman oestrogen receptor positive breast cancer previous experience recurrence progression non-steroidal aromatase inhibitor ( NSAI ) therapy .</brief_summary>
	<brief_title>An Open Label Study Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced Metastatic Breast Cancer Treated With Everolimus ( RAD001 ) With Exemestane , With Exploratory Epigenetic Marker Analysis</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Histological cytological confirmation oestrogen receptor positive ( ER+ ) and/or progesterone receptor positive ( PgR+ ) , human epidermal growth factor receptor 2 ( HER2 ) negative breast cancer . Availability archival tumour tissue ( tissue block slide send central laboratory analysis ) . Postmenopausal woman . The investigator must confirm postmenopausal status . Postmenopausal status define either : Age ≥ 55 year one year amenorrhea Age &lt; 55 year one year amenorrhea postmenopausal level FSH LH per local institutional standard Prior hysterectomy postmenopausal level Follicle stimulate hormone ( FSH ) Luteinizing Hormone ( LH ) per local institutional standard Surgical menopause bilateral oophorectomy Disease progression follow prior therapy NSAI , define : Recurrence completion adjuvant treatment include letrozole anastrozole , Progression follow completion letrozole anastrozole treatment locally advance metastatic breast cancer Note : Nonsteroidal aromatase inhibitor ( i.e . letrozole anastrozole ) last treatment prior enrollment . Other prior anticancer therapy , e.g . tamoxifen , fulvestrant , exemestane also allow . Patients must recover grade 1 good adverse event ( except alopecia ) relate previous therapy prior enrollment . Radiological evidence recurrence progression last systemic therapy prior enrollment . Patients must : At least one lesion accurately measure Bone lesion : lytic mixed ( lytic + sclerotic ) absence measurable disease Adequate bone marrow coagulation function show : Absolute neutrophil count ( ANC ) ≥ 1.5 109/L Platelets ≥ 100 ×109/L Hemoglobin ( Hb ) ≥ 9.0 g/dL International Normalized Ratio ( INR ) ≤ 2 . Adequate liver function show : Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 ULN ( ≤ 5 hepatic metastasis present ) Total serum bilirubin ≤ 1.5 × ULN ( ≤ 3 × ULN patient know Gilbert Syndrome ) Adequate renal function show : Serum creatinine ≤ 1.5 × ULN Fasting serum cholesterol ≤ 300 mg/dl 7.75 mmol/L fast triglyceride ≤ 2.5 × ULN . In case one threshold exceed , patient include initiation statin therapy mention value achieve Eastern Cooperative Oncology Group ( ECOG ) performance status PS &lt; / 2 Written inform consent obtain screening procedure accord local guideline . HER2overexpressing patient local laboratory testing ( IHC 3+ stain situ hybridization positive ) . Premenopausal , pregnant , lactating woman . Known hypersensitivity mammilian target Rapamycin ( mTOR ) inhibitor , e.g . sirolimus ( rapamycin ) excipients . Known hypersensitivity exemestane , active substance excipients . Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucose galactose malabsorption . Radiotherapy within four week prior enrollment except case localize radiotherapy analgesic purpose lytic lesion risk fracture complete within two week prior enrollment . Patients must recover radiotherapy toxicity prior enrollment . Currently receive hormone replacement therapy , unless discontinue prior enrollment . Patients receive concomitant immunosuppressive agent chronic corticosteroid use , time study entry except case outline : Prolonged systemic corticosteroid treatment study , except topical application ( e.g . rash ) , inhale spray ( e.g . obstructive airway disease ) , eye drop local injection ( e.g . intraarticular ) give . However : short duration ( &lt; 2 week ) systemic corticosteroid allow ( e.g . chronic obstructive pulmonary disease , antiemetic ) low dos corticosteroid brain metastasis treatment allow Patients symptomatic visceral metastasis ( e.g . significant dyspnoea relate pulmonary lymphangitic carcinomatosis lung metastases clinically meaningful symptomatic liver metastasis ) Symptomatic brain Central Nervous system ( CNS ) metastases . Active , bleed diathesis , oral antivitamin K medication ( except low dose warfarin , low molecular weight heparin ( LMWH ) acetylsalicylic acid equivalent , long INR 2.0 ) Any severe / uncontrolled medical condition : Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior enrollment , serious uncontrolled cardiac arrhythmia Uncontrolled diabetes define fast serum glucose &gt; 1.5 × ULN Acute chronic , active infectious disorder ( except Hep B Hep C positive patient ) nonmalignant medical illness uncontrolled whose control may jeopardize complication study therapy Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhoea , malabsorption syndrome ) Significant symptomatic deterioration lung function . If clinically indicate , pulmonary function test include measure predict lung volume , DLco , O2 saturation rest room air consider exclude restrictive pulmonary disease , pneumonitis pulmonary infiltrates . Patients treat drug recognize strong inhibitor inducer isoenzyme CYP3A ( rifabutin , rifampicin , clarithromycin , ketoconazole , itraconazole , voriconazole , ritonavir , telithromycin ) within last 5 day prior enrollment History noncompliance medical regimens Patients unwilling unable comply protocol Another malignancy within 5 year prior randomization , exception adequately treat insitu carcinoma cervix , uteri , basal squamous cell carcinoma nonmelanomatous skin cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Breast disease</keyword>
	<keyword>Skin disease</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Antibiotics , Antineoplastic</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Aromatase Inhibitors</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
</DOC>